Philogen logo SIENA, Italy - February 17, 2022 - (Newswire.com) Philogen S.p.A. ("Philogen" or "the Company"), a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, is pleased to announce that France's National Agency for the Saf.